These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 38755968)

  • 1. Research Advances in the Roles of N6-Methyladenosine Modification in Ovarian Cancer.
    Zhang Y; Ling Y; Zhou Y; Shi X; Shen F; Zhou J; Chen Y; Yang F; Gu Y; Wang J
    Cancer Control; 2024; 31():10732748241256819. PubMed ID: 38755968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N6-Methyladenosine-Related RNA Signature Predicting the Prognosis of Ovarian Cancer.
    Jiao J; Jiang L; Luo Y
    Recent Pat Anticancer Drug Discov; 2021; 16(3):407-416. PubMed ID: 34137363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene Signatures and Prognostic Values of m6A RNA Methylation Regulators in Ovarian Cancer.
    Han X; Liu J; Cheng G; Cui S
    Cancer Control; 2020; 27(1):1073274820960460. PubMed ID: 32951457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Research advances of N6-methyladenosine in diagnosis and therapy of pancreatic cancer.
    Chen S; Ren H; Zhang X; Chang L; Wang Z; Wu H; Zhang J; Ren J; Zhou L
    J Clin Lab Anal; 2022 Sep; 36(9):e24611. PubMed ID: 35837987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of m6A methylation modification in ovarian cancer.
    Chang LL; Xu XQ; Liu XL; Guo QQ; Fan YN; He BX; Zhang WZ
    Cancer Cell Int; 2021 Dec; 21(1):663. PubMed ID: 34895230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of RNA modification N6-methyladenosine in human cancer.
    Zhou Z; Lv J; Yu H; Han J; Yang X; Feng D; Wu Q; Yuan B; Lu Q; Yang H
    Mol Cancer; 2020 Jun; 19(1):104. PubMed ID: 32513173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. m6A modification of RNA in cervical cancer: role and clinical perspectives.
    Gao Y; Guo Q; Yu L
    RNA Biol; 2024 Jan; 21(1):49-61. PubMed ID: 39344658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LINC02489 with m6a modification increase paclitaxel sensitivity by inhibiting migration and invasion of ovarian cancer cells.
    Xie Y; Wang L; Luo Y; Chen H; Yang Y; Shen Q; Cao G
    Biotechnol Genet Eng Rev; 2023 Oct; 39(2):1128-1142. PubMed ID: 36703541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N6-methyladenosine-dependent signaling in colorectal cancer: Functions and clinical potential.
    Liu S; Liu M; Li Y; Song Q
    Crit Rev Oncol Hematol; 2024 Jun; 198():104360. PubMed ID: 38615872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification and validation of a seven m6A-related lncRNAs signature predicting prognosis of ovarian cancer.
    Song Y; Qu H
    BMC Cancer; 2022 Jun; 22(1):633. PubMed ID: 35676619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNA m6A methylation regulators in ovarian cancer.
    Guo J; Zheng J; Zhang H; Tong J
    Cancer Cell Int; 2021 Nov; 21(1):609. PubMed ID: 34794452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. N6-methyladenosine methylation regulator FTO promotes oxidative stress and induces cell apoptosis in ovarian cancer.
    Wu J; Wang X; Li X
    Epigenomics; 2022 Dec; 14(23):1509-1522. PubMed ID: 36815224
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential role of RNA N6-methyladenosine in Cancer progression.
    Wang T; Kong S; Tao M; Ju S
    Mol Cancer; 2020 May; 19(1):88. PubMed ID: 32398132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RNA N6-methyladenosine demethylase FTO promotes breast tumor progression through inhibiting BNIP3.
    Niu Y; Lin Z; Wan A; Chen H; Liang H; Sun L; Wang Y; Li X; Xiong XF; Wei B; Wu X; Wan G
    Mol Cancer; 2019 Mar; 18(1):46. PubMed ID: 30922314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of N6-methyladenosine RNA modification in cancer.
    Qu Y; Gao N; Zhang S; Gao L; He B; Wang C; Gong C; Shi Q; Li Z; Yang S; Xiao Y
    MedComm (2020); 2024 Sep; 5(9):e715. PubMed ID: 39252821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study.
    Yang L; Liu J; Jin Y; Xing J; Zhang J; Chen X; Yu A
    Sci Rep; 2024 May; 14(1):10427. PubMed ID: 38714753
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-methyladenosine methyltransferase KIAA1429 promoted ovarian cancer aerobic glycolysis and progression through enhancing ENO1 expression.
    Gan L; Zhao S; Gao Y; Qi Y; Su M; Wang A; Cai H
    Biol Direct; 2023 Oct; 18(1):64. PubMed ID: 37807062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The emerging roles of N6-methyladenosine (m6A) deregulation in liver carcinogenesis.
    Chen M; Wong CM
    Mol Cancer; 2020 Feb; 19(1):44. PubMed ID: 32111216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Roles and therapeutic implications of m6A modification in cancer immunotherapy.
    Pan J; Huang T; Deng Z; Zou C
    Front Immunol; 2023; 14():1132601. PubMed ID: 36960074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functions of N6-methyladenosine and its role in cancer.
    He L; Li H; Wu A; Peng Y; Shu G; Yin G
    Mol Cancer; 2019 Dec; 18(1):176. PubMed ID: 31801551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.